Copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Mar 15, 2021; 13(3): 157-160
Published online Mar 15, 2021. doi: 10.4251/wjgo.v13.i3.157
Published online Mar 15, 2021. doi: 10.4251/wjgo.v13.i3.157
Angiotensin-converting enzyme 2 connects COVID-19 with cancer and cancer immunotherapy
Xiao-Sheng Wang, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China
Author contributions: Wang XS conceived of and wrote the manuscript.
Conflict-of-interest statement: No potential conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xiao-Sheng Wang, PhD, Associate Professor, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, No. 639 Longmian Avenue, Nanjing 211198, Jiangsu Province, China. xiaosheng.wang@cpu.edu.cn
Received: December 16, 2020
Peer-review started: December 16, 2020
First decision: January 11, 2021
Revised: January 18, 2021
Accepted: February 4, 2021
Article in press: February 4, 2021
Published online: March 15, 2021
Peer-review started: December 16, 2020
First decision: January 11, 2021
Revised: January 18, 2021
Accepted: February 4, 2021
Article in press: February 4, 2021
Published online: March 15, 2021
Core Tip
Core Tip: Angiotensin-converting enzyme 2 (ACE2) is a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) host cell receptor and plays a crucial role in SARS-CoV-2 invading human cells to cause coronavirus disease 2019 (COVID-19). ACE2 also plays a role in preventing tumor progression and promoting cancer immunotherapy response. Thus, the use of ACE2 inhibitors to prevent and treat COVID-19 should be carried out cautiously in cancer patients.